Rigel Pharmaceuticals, Inc. (RIGL)

1.1500 +0.0600 (+5.50%) 收市：04:00PM EDT

Rigel Pharmaceuticals, Inc.

611 Gateway Blvd
Suite 900
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

版塊: Healthcare
行業: Biotechnology
全職員工: 147

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Raul R. Rodriguez	President, CEO & Director	1.17M	無	1961
Mr. Dean L. Schorno CPA	Executive VP & CFO	736.72k	無	1963
Mr. Raymond J. Furey J.D.	Executive VP, General Counsel & Corporate Secretary	683k	無	1968
Mr. David A. Santos	Executive VP & Chief Commercial Officer	737.18k	無	1963
Ms. Julie Patel	Senior VP of Human Resources	無	無	無
Dr. Esteban S. Masuda	Executive Vice President of Research	537.21k	無	1962
Mr. Joseph Lasaga	Executive VP & Chief Business Officer	無	無	1975
Dr. Lisa Rojkjaer M.D.	Executive VP & Chief Medical Officer	無	無	1966
Mr. Tarek Sallam	Vice President of Marketing	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

公司管治

截至 2024年5月1日 止，Rigel Pharmaceuticals, Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：6；董事會：3；股東權利：3；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。